The novel mitochondria-targeted hydrogen sulfide (H2S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro  by Gerő, Domokos et al.
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The  development  of  diabetic  vascular  complications  is  initiated,  at least  in part, by mitochondrial  reactive
oxygen  species  (ROS)  production  in  endothelial  cells.  Hyperglycemia  induces  superoxide  production  in
the  mitochondria  and  initiates  changes  in  the  mitochondrial  membrane  potential  that  leads  to mitochon-
drial  dysfunction.  Hydrogen  sulﬁde  (H2S)  supplementation  has been  shown  to reduce  the  mitochondrial
oxidant  production  and  shows  efﬁcacy  against  diabetic  vascular  damage  in  vivo.  However,  the half-life
of H2S  is very  short  and  it is not  speciﬁc  for the mitochondria.  We  have  therefore  evaluated  two  novel
mitochondria-targeted  anethole  dithiolethione  and hydroxythiobenzamide  H2S donors  (AP39  and  AP123
respectively)  at preventing  hyperglycemia-induced  oxidative  stress  and  metabolic  changes  in microvas-
cular  endothelial  cells  in  vitro. Hyperglycemia  (HG)  induced  signiﬁcant  increase  in the  activity  of  the  citric
acid cycle  and  led  to elevated  mitochondrial  membrane  potential.  Mitochondrial  oxidant  production  was
increased  and  the  mitochondrial  electron  transport  decreased  in hyperglycemic  cells.  AP39  and  AP123
(30–300  nM)  decreased  HG-induced  hyperpolarisation  of the  mitochondrial  membrane  and  inhibited
the  mitochondrial  oxidant  production.  Both  H2S donors  (30–300  nM)  increased  the  electron  transport  at
respiratory  complex  III and  improved  the  cellular  metabolism.  Targeting  H2S to  mitochondria  retained
the  cytoprotective  effect  of  H2S against  glucose-induced  damage  in endothelial  cells  suggesting  that  the
molecular  target  of H2S action  is within  the mitochondria.  Mitochondrial  targeting  of H2S also  induced
>1000-fold  increase  in  the  potency  of  H2S against  hyperglycemia-induced  injury.  The  high potency  and
long-lasting  effect  elicited  by  these  H2S donors  strongly  suggests  that  these  compounds  could  be  useful
against  diabetic  vascular  complications.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Diabetic complications are responsible for the majority of
xpenses associated with diabetes treatment and the costs of dia-
etes that currently accounts for 10% of total healthcare costs, is
rojected to increase to 17% of health resource expenditure over
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ttp://dx.doi.org/10.1016/j.phrs.2016.08.019
043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uthe next 20 years [1]. Diabetes diagnostic criteria were established
based on the increased risk of microvascular and cardiovascular
complications in patients with increased plasma glucose level [2]
and glycemic control represent the foundation of diabetes ther-
apy, still it provides little protection against cardiovascular disease
(CVD) [3]. Since glucose control is ineffective against cardiovascu-
lar events in diabetic patients [3–5], it is important to ﬁnd novel
therapies that reduce the progression of cardiovascular disease in
diabetes. Hyperglycemia induces oxidant production in the ves-
sels and oxidative stress is considered as a major contributor to
vascular damage [6]. Oxidative stress induced by hyperglycemia
persists in the cells long after glucose levels are normalised and
this phenomenon is known as “glucose memory” [7]. The limited
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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VD risk reduction in diabetes may  be explained by the persistence
f deleterious downstream effects that occur after intermittent
yperglycemic episodes, despite lower glycated hemoglobin lev-
ls.
Hyperglycemia-induced mitochondrial superoxide generation
s an upstream player in the development of endothelial dysfunc-
ion and it is responsible for the activation of other sources of
xidants in the cells [8]. In endothelial cells, high glucose supply
esults in increased glucose oxidation: more electron donors are
ushed into the electron transport chain and the voltage gradi-
nt across the mitochondrial membrane increases. The increased
ransmembrane voltage induces electron leakage between com-
lexes II and III and the inappropriate transfer of electrons to
olecular oxygen generates superoxide [9]. If the mitochondrial
otential is normalised in the cells by uncoupling protein-1 (UCP-1)
verexpression or the mitochondrial respiratory chain is inacti-
ated by mitochondrial DNA depletion hyperglycemia does not
enerate superoxide [8]. Blockage of mitochondrial superoxide
eneration by the above methods or neutralisation by manganese
uperoxide dismutase (MnSOD) inhibits other sources of oxidants
n endothelial cells: the activation of protein kinase C (PKC) and
he polyol pathway, the formation of advanced glycation end
roduct (AGE) and the hexosamine pathway [8]. Similarly, we
ound that mitochondrial superoxide scavenging using paroxetine
10] or induction of uncoupling protein-2 (UCP-2) also blocked
he glucose-induced oxidant production in endothelial cells [11].
hile these methods all reduce the mitochondrial ROS produc-
ion and the associated cellular damage, neither ROS scavenging
or mitochondrial uncoupling fully restore the mitochondrial
nergy production. If electrons are used for superoxide genera-
ion and the protons are released through uncoupling proteins,
here will be a drop in ATP production via oxidative phosphory-
ation.
H2S is an endogenously produced ‘gasotransmitter’ that plays
ey roles in regulating vascular tone, inﬂammation, cell death
nd proliferation as well as vascular protection [12–15]. Lower
2S bioavailability has been reported in the diabetic vascula-
ure in humans and correlates to poorer microcirculatory blood
ow [16]. Impaired vascular H2S synthesis and/or bioavailability
s also observed in the vasculature of several animal models of
iabetes induced either pharmacologically- (e.g. streptozotocin-
nduced [17]) or genetically-induced (e.g. Akita [18], db/db [19] and
OD mice [20]). The ‘loss’ of vasculoprotective H2S is thought to
ontribute to vascular endothelial dysfunction and disease pathol-
gy suggesting approaches to increase H2S bioavailability could be
f therapeutic beneﬁt in diabetes and vascular disease. One key
echanism by which H2S is beneﬁcial is by serving as an inor-
anic electron donor to the respiratory chain [21]. The oxidation
f H2S is a multi-step process and electron transfer to the res-
iratory chain may  be dissociated from the subsequent steps of
roton transfer and oxygen consumption [22]. Thus, unlike the
ain electron donors, nicotinamide adenine dinucleotide (NADH)
nd ﬂavin adenine dinucleotide (FADH2), H2S can provide the res-
iratory chain with electrons only. This effect of H2S is supported
y the ﬁndings that exogenous H2S, albeit at high concentrations,
an normalise the mitochondrial membrane potential and reduce
itochondrial superoxide generation in hyperglycemic endothelial
ells and also prevent the development of endothelial dysfunc-
ion in streptozotocin-induced diabetes [17,23]. Furthermore, H2S,
n the form of inorganic salts (e.g. NaSH and Na2S) have protec-
ive effects against diabetic retinopathy and nephropathy [24–26]
nd also has cardioprotective effects in diabetic models [19,27,28].
he administration of H2S using its sodium salts is inconvenient in
ong-term diseases because it has a short half-life and lacks cellular
argeting. Natural sources of H2S such as garlic were therefore, also
ested with similar results: garlic extract protects against diabeticsearch 113 (2016) 186–198 187
nephropathy, vasculopathy and cardiomyopathy [29–31] and its
active constituents were found to be diallyldisulﬁde (DADS) and
diallyltrisulﬁde (DATS) [32], which are slower H2S donors than
Na2S [33]. Since the protective effect of H2S is mostly mitochon-
drial in the hyperglycemic endothelium, we tested the efﬁcacy
of novel mitochondria-targeted H2S donors against the glucose-
induced oxidant production. AP39 is a slow-release H2S donor
that was  shown to accumulate in the mitochondria [36,37] and
protect against oxidative stress-induced mitochondrial DNA and
protein damage in endothelial cells [34]. We compared the efﬁ-
cacy of AP39 and AP123, a newer mitochondrial H2S donor, against
glucose-induced endothelial dysfunction and we found that mito-
chondrial slow-release H2S donors are >1000-fold more potent
than Na2S against hyperglycemia-induced oxidant production and
also have beneﬁcial effect on cellular bioenergetics in endothelial
cells.
2. Methods
2.1. Synthesis of mitochondria-targeted H2S donor AP123 (10-(4-
carbamothioylphenoxy)-10-oxodecyl)triphenylphosphonium
bromide)
AP39 was  synthesised as previously described by us [35],
extinction coefﬁcient in DMSO (400nm = 6162 M−1 cm−1;
(327nm = 12000 M−1 cm−1). AP123 was synthesised using
the following procedure: acetonitrile (8 cm3) was  added to
10-bromodecanoic acid (400 mg,  1.59 mmol) and triphenylphos-
phine (418 mg,  1.59 mmol) and the resulting mixture was
stirred and heated under reﬂux for 48 h [36]. The acetoni-
trile was evaporated in vacuo and the colourless, oily residue
was triturated with toluene (3 × 10 cm3) before thorough dry-
ing on a rotary evaporator and dissolution in dichloromethane
(15 cm3). At room temperature, 4-hydroxythiobenzamide (244 mg,
1.59 mmol) was  added to the stirred solution, followed by a solu-
tion of N,N-dicyclohexylcarbodiimide (330 mg,  1.60 mmol) in
dichloromethane (8 cm3) and 4-dimethylaminopyridine (10 mg,
0.08 mmol). After stirring for 22 h, the reaction mixture was ﬁl-
tered through a cotton wool plug and after removal of the solvent
in vacuo, the crude product was applied as a dichloromethane
solution onto a silica gel ﬂash chromatography column ca 120 cm3
silica gel, 3 cm diameter column). After ﬂushing the silica gel with
ethyl acetate (200 cm3), the product was eluted with methanol
(200 cm3) and after evaporation of the solvent in vacuo,  the product
was re-dissolved in dichloromethane (20 cm3) and the resulting
solution was dried (magnesium sulfate), ﬁltered and evaporated
in vacuo to give the title compound (516 mg,  50%) as a crisp,
yellow foam (found [M-Br]+ (ES+) 568.2429, C35H39NO2PS requires
568.2434); max (KBr disc)/cm−1 3415 (m), 3055 (m), 2925 (s),
2853 (s), 1752 (s) (C O), 1619 (s), 1599 (s), 1587 (m), 1504 (m),
1483 (m), 1464 (w), 1438 (s), 1384 (m), 1311 (m), 1264 (m), 1205
(s), 1167 (s), 1112 (s), 1014 (m), 995 (m), 892 (m)  and 851 (w);
1H NMR  (300 MHz, CDCl3) 9.26 (1H, br s, NH), 8.20 (2H, part of
AA’BB’, J = 8.5 Hz, aryl CH), 7.89-7.62 (16H, complex, phenyl CH
and NH), 7.02 (2H, part of AA’BB’, J = 8.5 Hz, aryl CH), 3.50 (2H, m,
CH2P+), 2.52, (2H, t, J = 7 Hz, CH2C(O)), 1.72-1.55 and 1.42-1.13 (6H
and 8H, 2 x broad m,  (CH2)7C(O)); 31P NMR  (121 MHz, CDCl3) 24.0
(P+); 13C NMR  (100 MHz, CDCl3) 200.0 (C = S), 171.8 (C O), 153.5
(aryl C-O), 135.6 (aryl C-C(S)), 135.2 (d, J = 3 Hz, phenyl C-H), 133.5
(d, J = 10 Hz, 2 x phenyl C-H), 130.5 (d, J = 13 Hz, 2 x phenyl C-H),
129.7 (aryl C-H), 121.0 (aryl C-H), 118.1 (d, J = 86 Hz, phenyl C-P+),
34.2 (CH2C(O)), 30.3 (CH2), 30.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6
(CH2), 28.5 (CH2), 24.5 (CH2), 22.9 (CH2) and 22.4 (d, J = 18 Hz,
CH2P+), extinction coefﬁcient in DMSO (308 nm = 5275 M−1 cm−1;
(262 nm = 8108 M−1 cm−1).
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.2. H2S release detection
H2S donors were dissolved and diluted in DMSO. Com-
ounds or vehicle were added in 1/10 vol and mixed with
MEM supplemented with 10% FBS and 0.5 mg/ml  MTT. Free
2S as strong reducing agent reacts with the tetrazolium dye 3-
4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
MTT, Calbiochem, EMD  BioSciences, San Diego, CA) and forms
urple colour formazan. Changes in absorbance were recorded
very 24 h on a microplate reader (Molecular Devices Spectramax
2e, Sunnyvale, CA) at 570 nm with background measurement at
90 nm.  The reaction was carried out in a humidiﬁed incubator
t 37 ◦C with 5% CO2 atmosphere to closely mimic  the cell cul-
ure conditions and minimise evaporation. H2S calibration curve
as created by preparing serial dilutions of freshly dissolved Na2S
Alpha Aesar, Haverhill, MA)  and by measuring the reducing capac-
ty. The slow release H2S donors liberate H2S over several days and
he low background of MTT  reduction allows H2S detection up to 2
eeks. The H2S generation is shown as the cumulative increase or
aily change in absorbance with respective H2S values.
.3. Cell culture and toxicity assay
b.End3 murine microvascular endothelial cells were obtained
rom the European Collection of Cell Cultures (ECACC, Salisbury,
K) as described, passage numbers 24–30 were used [37]. The
.End3 cells were established from brain endothelial cells of 129/Sv
ice by immortalisation with the Polyoma virus middle T-antigen
37]. The cells were maintained in Dulbecco’s modiﬁed Eagle’s
edium (DMEM) (Biochrom AG, Berlin, Germany) containing 1 g/l
lucose supplemented with 10% fetal bovine serum (FBS, Hyclone,
ogan, UT), 1% non-essential amino acids, 100 IU/ml penicillin and
00 g/ml streptomycin (Invitrogen, Carlsbad, CA) at 37 ◦C in 5%
O2 atmosphere [10,11].
b.END3 endothelial cells (20 000/well) were seeded in 96 well
lates and cultured in DMEM containing 1 g/l glucose supple-
ented with 10% FBS, 1% non-essential amino acids and antibiotics
t 37 ◦C in 5% CO2 atmosphere for 5 days. H2S donors were diluted
n PBS containing 10% DMSO and added in 1/20 vol, then cells were
ncubated at 37 ◦C for 24 h. Non-mitochondrial H2S donors were
dded in the concentration range of 100 nM to 1 mM and mito-
hondrial H2S donors in the range of 10 nM to 100 M.  After 24 h,
he supernatant was saved to detect LDH release and fresh culture
edium supplemented with 0.5 mg/ml  MTT  was added to the cells.
TT  and LDH assays were performed as detailed below. The cellu-
ar viability values and percent cell lysis values were plotted and
he 50% toxic concentration was calculated using Prism 6 analysis
oftware (GraphPad Software, Inc., La Jolla, CA).
.4. In situ detection of H2S in endothelial cells
b.End3 cells (2 × 105/well) were seeded on 4-well Nunc Lab-Tek
hambered coverglass (Nalge Nunc, Rochester, NY) and cultured
vernight. H2S donor compounds were diluted in PBS and DMSO
nd were added at 30 M ﬁnal concentration in 1/20 culture vol-
me. The cells were treated with the compounds at 37 ◦C for
 h, followed by loading with ﬂuorescent H2S sensor 7-azido-4-
ethylcoumarin (AzMc) (40 nM,  Sigma-Aldrich, St. Louis, MO)  and
itotracker Green FM (200 M,  Life Technologies, Carlsbad, CA)
itochondrial stain at 37 ◦C for 1 h to detect H2S release simultane-
usly with the endogenous H2S production. AzMc ﬂuorescence and
he MitoTracker signal were detected on a Nikon TE2000 inverted
icroscope (Nikon UK Limited, Surrey, UK) using a Hamamatsu
RCA-ER monochrome camera (Hamamatsu Photonics UK Ltd.,search 113 (2016) 186–198
Hertfordshire). The H2S signal is shown in green and the Mito-
Tracker signal in red.
2.5. High glucose-induced endothelial dysfunction
Mitochondrial ROS generation was induced in b.End3 endothe-
lial cells by prolonged exposure to high glucose as we previously
described [10,11]. Microvascular endothelial cells (20,000/well)
were seeded into 96-well tissue culture plates and were cultured
for 24 h. Hyperglycemia (40 mM glucose) was initiated by replacing
the culture medium with fresh DMEM containing 7.2 g/l glucose
supplemented with 10% FBS, 1% non-essential amino acids, 100
IU/ml penicillin and 100 g/ml streptomycin and the cells were
exposed to high glucose level for 7 days. The culture medium was
supplemented with pyruvate (10 mM)  as fresh source of energy
after 3 days of exposure. H2S donor compounds were dissolved
in dimethyl sulfoxide (DMSO) and dilutions were made in phos-
phate buffered saline (PBS) to administer the compounds in 1/20
culture volume with ﬁnal DMSO concentration of 0.5%. The cells
were treated with the compounds for 3 days by administering the
drugs on the 4th day of the hyperglycemic exposure.
2.6. MTT  and LDH assays
The MTT  assay and LDH activity measurements were performed
as previously described [38,39]. Brieﬂy, the cells were incubated
in culture medium containing 0.5 mg/ml  MTT for 1 h at 37 ◦C at
10% CO2 atmosphere. The converted formazan dye was dissolved
in isopropanol and the absorbance was  measured at 570 nm with
background measurement at 690 nm.  Absorbance values are shown
as the cellular MTT  conversion rate (metabolic activity) in hyper-
glycemic cells. Cellular viability rates are calculated using serial
dilutions of cells and the percent survival rates compared to vehicle
treated controls were calculated.
Total LDH content of the cells was  measured by lysing the
cells in 0.15 M saline containing 1% Triton-X-100 and measuring
the LDH activity by adding 100 l LDH assay reagent containing
110 mM lactic acid, 1350 mM nicotinamide adenine dinucle-
otide (NAD+), 290 mM  N-methylphenazonium methyl sulfate
(PMS), 685 mM 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-
tetrazolium chloride (INT) and 200 mM Tris (pH 8.2). The changes
in absorbance were read kinetically at 492 nm for 15 min (kinetic
LDH assay). LDH activity values are shown as Vmax values. In the
toxicity assay, cell death was  measured by LDH release in the cell
culture supernatant (30 l/well) after 24 h exposure.
2.7. Measurement of mitochondrial ROS production
Measurements of the mitochondrial superoxide generation by
MitoSOX Red and the cellular reactive oxygen species (ROS) pro-
duction by CM-H2DCFDA were previously described [10]. After the
hyperglycemia exposure the cells were loaded with the mitochon-
drial superoxide sensor MitoSOXTM Red (2.5 M,  Life Technologies,
Carlsbad, CA) or with the cell-permeable ROS indicator 5-
(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate
(CM-H2DCFDA, 10 M,  Life Technologies, Carlsbad, CA) and DNA
stain Hoechst 33342 (10 M)  for 25 min. Reading medium (PBS
supplemented with 1 g/l glucose and 10% bovine growth serum
(BGS, Hyclone, Logan, UT)) was added to the cells and the oxidation
of MitoSOXTM Red (Ex/Em: 530/590 nm)  or CM-H2DCFDA (Ex/Em:
485/528 nm)  was recorded kinetically on Synergy 2 plate reader
(BioTek, Winooski, VT) at 37 ◦C for 35 min. ROS production is shown
as the Vmax value of the ﬂuorescence probe oxidation or as percent
values of Vmax values of control cells. The ﬂuorescence of Hoechst
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3342 (Ex/Em: 360/460 nm)  was used to conﬁrm that there was  no
hange in the cellular viability.
.8. Mitochondrial membrane potential
The mitochondrial potential was measured with JC-1 (Sigma-
ldrich, St. Louis, MO)  ﬂuorescent probe as previously described
11,40]. The cells were loaded with the dye by exposing them to JC-
 stain solution containing 10 M JC-1 and 0.6 mM -cyclodextrin
Sigma-Aldrich, St. Louis, MO)  in OptiMEM I medium at 37 ◦C for
0 min. Subsequently, the cells were washed in phosphate buffered
aline (PBS) and the red (Ex/Em: 530/590 nm)  and green (Ex/Em:
85/528 nm)  ﬂuorescence was measured on a microplate reader
Synergy 2, Biotek, Winooski, VT, USA). The mitochondrial potential
s expressed as the relative ratio of the mitochondrial J-aggregates
red ﬂuorescence) and the cytoplasmic monomer form of the dye
green ﬂuorescence).
.9. ATP assay
ATP concentration was determined by the commercially avail-
ble CellTiter-Glo® Luminescent Cell Viability Assay (Promega,
adison, WI)  as previously described [11]. The cells were lysed in
00 l of CellTiter-Glo reagent according to the manufacturer’s rec-
mmendations and the luminescent signal was recorded for 1 s on
 high sensitivity luminometer (Synergy Mx,  Biotek, Winooski, VT,
SA). The assay is based on ATP requiring luciferen-oxyluciferin
onversion mediated by a thermostable luciferase that generates
 stable “glow-type” luminescent signal. ATP standard (dilution
eries) was used to calculate the cellular ATP amount and the ATP
alues are shown as percent values of the normoglycemic controls.
.10. Extracellular ﬂux analysis
An XF24 Analyser (Seahorse Biosciences, Billerica, MA)  was used
o measure metabolic changes in b.End3 cells [10,41,42]. The XF24
reates a transient 7 l chamber in specialised microplates that
llows real-time measurement of oxygen and proton concentration
hanges via speciﬁc ﬂuorescent dyes and calculates OCR (oxygen
onsumption rate) and PPR (proton production rate), measures of
itochondrial respiration and glycolytic activity. The proton pro-
uction rate is expressed in pMol/min, while ECAR is in pH/min.
he OCR and PPR values represent the metabolism of cells, but may
lso reﬂect the number of viable cells.
b.End3 cells were exposed to hyperglycemia for 7 days and
reated with H2S donors for 3 days as described above. The culture
edium was changed to unbuffered DMEM (pH 7.4) containing
 mM glucose, 2 mM L-glutamine and 1 mM sodium pyruvate to
llow measurement of the proton production. After determining
he basal OCR and PPR values, oligomycin, FCCP and antimycin
 were injected through the ports of the Seahorse Flux Pak car-
ridge to reach ﬁnal concentrations of 1 g/ml, 0.3 M and 2 g/ml,
espectively, to determine the amount of oxygen consumption
inked to ATP production, the level of non-ATP-linked oxygen con-
umption (proton leak) as well as the maximal respiration capacity
nd the non-mitochondrial oxygen consumption.
.11. Respiratory complex II/III assay
Complex II + III activity was measured by the MitoTox Com-
lex II + III OXPHOS Activity Microplate assay (Abcam, Cambridge,
K). Respiratory complex II (succinate-ubiquinone oxidore-
uctase) transfers electrons from succinate to Complex III
ubiquinolcytochrome c oxidoreductase) via mobile electron shut-
le ubiquinone. Complex III transfers electrons to Complex IV
cytochrome c oxidase) via mobile electron carrier cytochrome c.search 113 (2016) 186–198 189
The assay measures cytochrome c reduction using succinate as sub-
strate (Complex II + III activity).
Bovine heart mitochondria were used as source of respira-
tory complexes. Complex I was  inhibited by rotenone (10 M)
to block electron transfer from NADH to ubiquinone and Com-
plex IV by potassium cyanide (2 mM)  to avoid the reoxidation of
cytochrome c. H2S donor compounds (10 nM to 10 M) were mixed
with mitochondria (30 g/ml) in the presence of succinate and
oxidised cytochrome c. Cytochrome c reduction was monitored
kinetically on a microplate reader (Molecular Devices Spectramax
M2e, Sunnyvale, CA) at 550 nm.  Mitochondrial complex II/III activ-
ity is shown as the maximum velocity of cytochrome c reduction
in mOD/min.
2.12. Statistics
One-way analysis of variance (ANOVA) was  used to detect dif-
ferences between groups. Post hoc comparisons were made using
Tukey’s test. A value of p < 0.05 was considered statistically sig-
niﬁcant. All statistical calculations were performed using Prism 6
analysis software (GraphPad Software, Inc., La Jolla, CA). Data are
shown as mean ± SEM values.
3. Results
3.1. Mitochondria-targeted H2S-donor compounds provide
controlled H2S release
H2S has been proposed as an endogenous antioxidant and plays
important roles in inﬂammatory and vascular diseases. The need for
slow-release H2S donor compounds was recognised since higher
concentrations of the gas are toxic, the half-life of H2S is very short
and simple salts like sodium hydrosulﬁde (NaSH) and sodium sul-
ﬁde (Na2S) can only provide instantaneous H2S generation [43–45].
Anethole dithiolethione (ADT-OH) and 4-hydroxythiobenzamide
(HTB) represent two simple moieties that release H2S slowly. Mito-
chondrial H2S donors (AP39 and AP123) were generated by linking
ADT-OH and HTB to a triphenylphosphonium mitochondrial target-
ing motif via a 10-carbon linker region (Fig. 1A and B, Supporting
information). This targeting group may  result in a 500-fold accumu-
lation of the drug in the mitochondria [46]. Both mitochondrial H2S
donors and their non-mitochondrial counterparts provide gradual
H2S production lasting for 7–10 days in cell culture medium (Fig. 1C
and D). The mitochondrial targeting group in AP39 does not change
the time course of H2S release by ADT-OH, but slightly slows down
the H2S liberation from HTB moiety in AP123 although the mech-
anism for this is not clear. HTB and AP123 contain a single sulfur
atom, thus they can release one H2S molecule per donor compound.
The expected molar amounts of H2S are produced over a 7-day-long
period. AP39 and ADT-OH contain 3 sulfur atoms and are possibly
capable of higher H2S release over 10 days of follow-up. With the
shorter period of H2S release, a steeper decrease is detectable in H2S
production for AP123 and HTB than for AP39 and ADT-OH (Fig. 1E
and F). While the kinetics are different, the total amount of H2S
production is comparable during a 3-day long treatment period:
approx. 0.6 mol  of H2S are produced by a mole the H2S donors
(Fig. 1G and H).
We investigated the cellular localisation of H2S production fol-
lowing the H2S donor administration to conﬁrm that the presence
of the mitochondrial targeting group increases the mitochondrial
H2S release. Endothelial cells treated with the compounds were
loaded with ﬂuorescent H2S sensor 7-azido-4-methylcoumarin
(AzMc) [27] and the H2S production was detected by ﬂuores-
cence microscopy (Fig. 2). Cells treated with the mitochondrial
donor compounds showed predominant mitochondrial H2S pro-
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Fig. 1. H2S release by mitochondrial H2S donors. A and B: The chemical structure of mitochondrial H2S donors: the H2S releasing groups anethole dithiolethione (ADT-OH)
in  AP39 (A) and 4-hydroxythiobenzamide (HTB) in AP123 (B) are bound by ester linkage to 10-carbon alkyl linker region and the triphenyl phosphonium mitochondrial
targeting group. C-D: The total amount of H2S released from non-mitochondrial (ADT-OH, HTB) and mitochondrial (AP39, AP123) H2S donors (100–500 M)  was detected
in  cell culture medium (DMEM supplemented with 10% FBS) for 10 days. E-F: Daily H2S release values are plotted with curve-ﬁtting results to highlight the donor compound
decomposition. G-H: The total amount of H2S liberated from mitochondrial and respective non-mitochondrial H2S donors over the ﬁrst 3-day long period is shown.
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Fig. 2. Localization of H2S release. b.End3 microvascular endothelial cells were pre-treated with H2S donor compounds (30 M,  ADT-OH, AP39, HTB and AP123), then loaded
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n  green. The H2S signal completely overlaps with the mitochondrial signal in mit
on-mitochondrial H2S donor-treated cells higher non-mitochondrial H2S signal is
uction. While mitochondrial H2S generation was  evident in all
ells, those treated with non-mitochondrial H2S donors showed
igher presence of extra-mitochondrial H2S than those treated
ith the mitochondrial donors. It has to be mentioned that the
ster linkage between the mitochondrial targeting moiety and the
2S donor group could be cleaved by cellular esterases increasing
he non-mitochondrial H2S production in cells treated with AP39
r AP123. However, mitochondrial but not cytoplasmic H2S was
apidly detected with each compound suggesting esterase cleavage
as minimal.
It is well established that H2S causes toxicity at high con-entrations by blocking the mitochondrial respiration. This effect
s believed to occur via inhibition of complex IV (cytochrome c
xidase) [47–49], but blockage of the mitochondrial respiration
ay  also occur as a consequence of H2S-mediated electron dona-ignal) are shown in red and the H2S production (AzMc signal) in the cells is shown
drial H2S donor treated cells (as displayed in the merged channels), while in the
table.
tion and reduction of the mitochondrial membrane potential. To
test the tolerability of H2S donor compounds, we exposed b.End3
endothelial cells to H2S donors in a wide concentration range (1
nM–10 mM)  and measured the cell survival after 24 h (Fig. 3).
All compounds were well tolerated at lower concentrations and
induced cell death in a narrow concentration range. Sodium sulﬁde
was tolerated by endothelial cells up to 300 M but induced cell
death above that (TC50 = 318.9 M).  The tolerance of HTB was  com-
parable to Na2S (TC50 = 165.5 M)  while ADT-OH had a lower TC50
value (TC50 = 69.5 M)  probably due to its higher H2S producing
capacity. (It has more sulfurs than the other compounds and could
release more than one H2S per drug molecule). The mitochondria-
targeted H2S donors caused no toxicity up to 1 M in endothelial
cells and the tolerable concentration was only one order of mag-
nitude lower than their non-mitochondrial counterparts (AP123:
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Fig. 3. Tolerability of H2S donors. b.End3 cells were treated with mitochondrial and non-mitochondrial H2S donor compounds for 24 h. A: The cellular viability was measured
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cy  the MTT assay. B: LDH release was detected by measuring the LDH activity in th
ells:  the mitochondrial H2S donors reduce the cell survival at lower concentration
C50 = 16.7 M,  AP39: TC50 = 7.7 M).  In summary, mitochondrial
2S donors are safe to use at sub-micromolar concentrations in
ndothelial cells.
.2. H2S donors inhibit the mitochondrial ROS production in
yperglycemic endothelial cells
High glucose-induced mitochondrial oxidant production plays
 central role in mitochondrial dysfunction in endothelial cells
8,10]. The respiratory chain is primarily responsible for the super-
xide generation in the mitochondria in hyperglycemia [8]. Since
his process requires electrons, extra protons are left behind and
n increase is induced in the transmembrane proton gradient.
itochondrial hyperpolarisation plays an important part in the
ncreased ROS production in hyperglycemia, since restoration of the
itochondrial potential blocks the mitochondrial superoxide gen-
ration [11]. H2S acts as an electron donor in the electron transport
hain and it is shown to normalise the membrane potential and
nhibit the mitochondrial ROS production in hyperglycemia [17].
he instant generation of H2S by NaSH or Na2S and the small por-
ion of mitochondrial H2S produced by these salts requiring their
se at high concentrations (and doses) are non-ideal in long-term
iseases, thus we tested the ROS-inhibitory effects of mitochondrial
low-release donors AP39 and AP123.
Both AP39 and AP123 signiﬁcantly reduced hyperglycemia-
nduced increase in the mitochondrial membrane potential at
ow nanomolar concentrations (Fig. 4A and D). Both compounds
educed the mitochondrial ROS production as detected by MitoSOX
ed (Fig. 4B and E) and also caused a slight decrease in the cellu-
ar ROS production as measured by CM-H2DCFDA (Fig. 4C and F).
P39 was more effective than AP123 that might be explained by
he higher H2S release of AP39. It is of note that a single treat-
ent of these mitochondrial donors provided protection over a
-day-long period at 1000-fold lower concentration than the previ-
usly reported cytoprotective concentration of H2S using repeated
dministration [17].
Mitochondrial dysfunction affects the cellular energy produc-
ion in hyperglycemic endothelial cells and results in a decrease
n the cellular ATP content after 7 days in b.End3 cells (Fig. 5A and
). Both AP39 and AP123 increased the cellular ATP content in a
oncentration-dependent manner (Fig. 5A and D) supporting the
ypothesis that H2S-donor-mediated electron donation increases
he mitochondrial ATP production [21]. Hyperglycemia did not
nduce changes in the cellular LDH activity in b.End3 endothelial
ells (Fig. 5B and E), but there was signiﬁcant increase in the cel-ulture supernatant. The non-mitochondrial H2S donors are better tolerated by the
lular MTT  converting capacity (Fig. 5C and F). This increase in the
cellular MTT  conversion was  probably a compensatory activation of
the citric acid cycle after long-term exposure to high extracellular
glucose. None of the compounds affected the cellular LDH activity
(Fig. 5B and E), but both compounds induced a signiﬁcant decrease
in the cellular MTT  conversion (Fig. 5C and F).
To test the effect of the compounds on cellular bioenerget-
ics, we performed metabolic proﬁling of b.End3 endothelial cells
treated with AP39 or AP123 for 3 days using extracellular ﬂux anal-
ysis (Fig. 6). Hyperglycemia induced subtle changes in the cellular
metabolism at this stage and there is no detectable change in the
basal OCR and ECAR (Fig. 6C and G), but the non-mitochondrial oxy-
gen consumption is higher in the hyperglycemic cells: the residual
OCR is elevated after blocking the mitochondria with oligomycin,
FCCP and antimycin A (Fig. 6A). There was  no detectable change
in oxygen consumption linked to mitochondrial ATP-production,
as measured by ATP synthase inhibition (Fig. 6D), but the mito-
chondrial H2S donors induced signiﬁcant increase in the respiratory
capacity (Fig. 6E) that is in line with prior results showing that
increased intra-mitochondrial H2S production affects this measure
[21]. The mitochondrial H2S donors improve the coupling efﬁciency
and signiﬁcantly reduce the proton leak (Fig. 6F) that can explain
the increased cellular ATP content in the cells (Fig. 5A and D) with-
out a measurable increase in oxygen consumption. There is no
change in the anaerobic metabolism in cells treated with mitochon-
drial H2S donors (Fig. 6G) that further conﬁrms that the compounds
do not inhibit mitochondrial respiration at low nanomolar con-
centrations. The predominantly mitochondrial localisation (Fig. 2)
strongly suggests that there was no interference with anaerobic
compensation following the inhibition of mitochondrial respiration
(Fig. 6H).
Mitochondrial H2S oxidation is a complex process that requires
three enzyme activities: 1) sulﬁde-quinone oxidoreductase (SQR)
catalyses the two-electron oxidation of H2S to the level of elemen-
tal sulfur by simultaneously reducing a cysteine disulﬁde such that
a persulﬁde group is formed, 2) sulfur dioxygenase oxidises per-
sulﬁdes to sulﬁte, consuming molecular oxygen and water and 3)
sulfur transferase produces thiosulfate by transferring a second
persulﬁde from SQR to sulﬁte [22]. During the ﬁrst step of H2S
oxidation, the electrons are fed into the respiratory chain via the
quinone pool (at the level of complex III). Oxygen consumption
occurs only through the second step of H S oxidation, thus feeding2
of electrons from H2S to the respiratory system does not necessar-
ily increase the cellular oxygen consumption. To conﬁrm that the
action of mitochondrial H2S donors increase the electron transfer,
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Fig. 4. Mitochondrial H2S donors protect against ROS production in hyperglycemic endothelial cells. A-B: b.End3 endothelial cells were exposed to high extracellular glucose
for  7 days with a single AP39 (A) or AP123 (B) treatment on the 4th day of hyperglycemia. The mitochondrial membrane potential was measured by JC-1, the mitochondrial
superoxide production by MitoSOX Red, and the cellular ROS production by CM-H2DCFDA. AP39 and AP123 restored the mitochondrial membrane potential and reduced the
ROS  production. (#p < 0.05 high glucose induced signiﬁcant increase in mitochondrial membrane potential or ROS production. *p <0.05 H2S donor compounds signiﬁcantly
reduced the mitochondrial membrane potential or ROS production compared to hyperglycemic control cells.).
Fig. 5. Mitochondrial H2S donors reduce the cellular hypermetabolism in hyperglycemic endothelial cells. A-B: b.End3 endothelial cells were exposed to high extracellular
glucose  for 7 days with a single AP39 (A) or AP123 (B) treatment on the 4th day of hyperglycemia. The MTT  reducing capacity, the total cellular LDH activity and the cellular
ATP  content were measured on the 7th day. (# p < 0.05 high glucose induced signiﬁcant changes in the cellular MTT  reducing capacity and ATP content. * p < 0.05 H2S donor
compounds signiﬁcantly reduced the MTT  reduction and increased the cellular ATP content.).
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Fig. 6. Mitochondrial H2S donors affect the cellular bioenergetics. b.End3 cells exposed to 7-day-long hyperglycemia were treated with AP39 (30 nM)  or AP123 (100 nM)
and  the metabolic proﬁle of the cells was studied by extracellular ﬂux analysis. Sequential injections of Oligomycin (1 g/ml), FCCP (0.3 M)  and antimycin A (2 g/ml) were
used  to measure A: the cellular oxygen consumption rate (OCR) and B: the extracellular acidiﬁcation rate (ECAR). C: Basal oxygen consumption, D: ATP production linked
oxygen  consumption (determined by oligomycin injection), E: total respiratory capacity (determined following the addition of FCCP) and F: the proton leak/basal respiration
w ring a
c
w
i
o
s
a
t
B
c
b
A
c
r
ras  determined. G: Acid production of basal metabolism and H: acid production du
apacity of the cells. (n = 3, *p < 0.05 compared to hyperglycemic control).
e performed a Complex II/III activity assay (Fig. 7). We  blocked
nput from Complex I by rotenone and inhibited cytochrome c
xidation (Complex IV) by potassium cyanide. In the presence of
ubstrate (succinate) Complex II transfers electrons to ubiquinone
nd Complex III to cytochrome c. The rate of cytochrome c reduc-
ion was measured in the absence or presence of AP39 or AP123.
oth compounds induced a concentration-dependent increase in
omplex III activity at concentrations below 2.5 M (Fig. 7A and B),
ut a decrease was detected at higher concentrations (5–10 M).
P123 induced similar changes to AP39 but at twice as high con-
entration possibly due to its lower H2S producing capacity. These
esults conﬁrmed that the compounds directly affected the respi-
atory complex activities.naerobic compensation was determined. AP39 and AP123 increase the respiratory
4. Discussion
The positive effects of H2S supplementation in diabetes were
conﬁrmed by several studies but long-term administration of H2S
remained a challenging issue [17,26,50,51]. H2S is volatile and has
short half-life in vivo, thus for long-term treatment its preferable
to use donor molecules (prodrugs) that release H2S at a controlled
rate. Several H2S donor compounds have been developed over the
last couple of years and various H2S producing chemistries have
been implicated but the control of H2S generation is still not per-
fect [43,52,53]. A further problem may arise from the side effects
caused by the by-products that are formed during H2S release,
thus in chronic diseases it is necessary to reduce the concentra-
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sig. 7. Mitochondrial H2S donors increase the respiratory Complex II/III activity. A
omplex I and IV blockade by rotenone and KCN, respectively. A: AP39 was added at
reated with AP123 (10 nM–10 M)  and the respiratory complex activity was moni
ion of the donors as much as possible since very long treatment
eriods are anticipated. One option is to deliver the H2S donors
o speciﬁc cell types or subcellular compartments to minimise the
ff-target effects. The subset of cell types, that are involved in dia-
etic complications and should beneﬁt from H2S supplementation,
ncludes capillary endothelial cells, mesangial cells, neurons and
chwann cells in peripheral nerves [8]. The glucose-induced dam-
ge is orchestrated by the mitochondria via superoxide generation
hat promotes all other oxidative stress pathways in diabetes [8],
hus mitochondrial oxidant production is the foremost target in the
ells.
It is difﬁcult to determine the mitochondrial concentration of
2S that might be associated with beneﬁcial effects in the cells
nd various methodologies produced strikingly different results,
ut the amount to produce stimulatory effect on cellular bioener-
etics is probably between 6 nM and 1 M [21,54,55]. In contrast,
 ∼1000-fold higher concentration (100–300 M exogenous H2S)
s needed to normalise the mitochondrial membrane potential
nd decrease the oxidant production in endothelial cells exposed
o high glucose concentrations, presumably because the H2S was
ot targeted to mitochondria [17]. Extracellular consumption of
2S, extra-mitochondrial metabolism and low penetration might
lso contribute to this huge difference. The amount of H2S that
locks complex IV and has inhibitory effect on the respiration
s no more than 1 order of magnitude higher than its stimula-
ory concentration [21,48,54,55] thus dosing can be challenging.
urthermore, it is unclear whether exogenous H2S supplemen-
ation affects the endogenous H2S production and whether the
oncentrations determined by prior assays truly reﬂect the ben-
ﬁcial amount of H2S on the long term. Overall, prior results
uggest that mitochondria-speciﬁc delivery of H2S can greatly
educe the therapeutic concentration of H2S donors. We  found that
P39 and AP123 were effective against hyperglycemic injury at
1000-fold lower concentrations than Na2S in endothelial cells. The
ytoprotective concentrations of the compounds (30–300 nM)  are
imilar to the values previously reported for AP39 [34,35,56,57].
he mitochondrial potential normalising and antioxidant effects
f the compounds also conﬁrm that H2S-mediated cytoprotection
epends on its mitochondrial effect in hyperglycemic endothe-
ial cells. It is unlikely that the mechanism of protection by
itochondrial-targeted H2S is by, or includes, upregulation of H2S
ynthesising enzymes as this has not been previously observed [58].: Cytochrome c reduction was monitored in bovine heart mitochondria following
–10 M and complex II/III activity was measured kinetically, B: Mitochondria were
 (*p < 0.05, H2S donors signiﬁcantly increased the respiratory complex activity).
The triphenylphosphonium targeting moiety of AP39 and AP123
provides potential–dependent drug accumulation in the mitochon-
dria [46] and also assures that H2S concentration is kept within a
safe range since normalisation of the mitochondrial potential will
reduce the drug accumulation. On the other hand, while the mito-
chondrial membrane potential is elevated the intra-mitochondrial
drug concentration will be higher than in cells with normal or
reduced mitochondrial potential at a given loading concentration of
the drug. Also, in metabolically active cells the high consumption of
H2S will not result in a drop in H2S donors, since mitochondria will
be replenished with new donor molecules by the re-equilibration
process and a relatively stable supply of H2S will be maintained by
the use of these donor compounds.
The antioxidant effect of AP39 and AP123 are comparable, but
the effective concentration of AP39 is slightly lower than that of
AP123 (Fig. 4). AP39 also induced an increase in complex II/III
activity at a slightly lower concentration than AP123 that supports
higher mitochondrial H2S release by AP39 (Fig. 7). Both AP39 and
AP123 provide H2S release for multiple days but AP39 is capable
of releasing more H2S than AP123 (Fig. 1). The higher H2S release
by AP39 is also evidenced by its lower toxic concentration: AP39
has a TC50 of 7.8 M while AP123’s TC50 is 16.7 M (Fig. 3); con-
centrations far exceeding their cytoprotective concentration range
(e.g. 10–300 nM,  Figs. 3–7). The toxic concentration of the non-
mitochondrial H2S donors ADT-OH and HTB is ten times higher
(69.5 M and 165.5 M,  respectively) than their mitochondrial
counterparts. The ten-fold increase in the mitochondrial H2S deliv-
ery achieved by the ester-linked mitochondrial targeting moiety
possibly suggests ten times lower risk of side effects caused by the
metabolites of the drugs. The molecular mechanism of H2S release
from 1,2-dithiole-3-thione compounds are still unclear [59], but
the mitochondrial redox environment may  affect this process. Fur-
thermore, H2S generation from ADT-OH or AP39 can occur through
multiple steps and each of these steps may be affected by various
metabolites in the mitochondria. On the other hand, HTB com-
pounds are more likely to liberate H2S through a single step that is
not affected by the metabolites, possibly allowing for better con-
trol of H2S generation. Interestingly, HTB is the chosen H2S donor
moiety in many novel H2S-releasing therapeutics including various
non-steroidal anti-inﬂammatory drugs (NSAIDs) and some of them
(e.g. the naproxen derivative ATB-346) already reached clinical trial
phases [52].
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H2S supplementation using natural products may  represent an
lternative approach for long-term treatment. Garlic is the most
ommonly used sulfur-rich nutrient that can provide H2S using it
ither freshly or its extract as a dietary supplement. Allicin (dial-
yl thiosulﬁnate), the main source of H2S in garlic, decomposes to
arious sulfur-containing compounds in aqueous solutions includ-
ng DADS and DATS [33,53,59]. DADS and DATS release H2S in a
hiol-dependent manner and they may  deplete the cellular glu-
athione pool [60–62]. While this chemical approach may  help
ontrol the H2S release, the loss of glutathione increases the risk
f oxidative damage in a pro-oxidant state like diabetes and H2S
oxicity was also associated with it [63]. Interestingly, the oppo-
ite effect of DADS, an increase in the cellular glutathione level was
lso reported after prolonged treatment periods [64] that may be
aused by H2S produced from the donors, since H2S itself increases
he glutathione concentration [65]. However, if this is the case the
levated glutathione content should result in further H2S genera-
ion from thiol-dependent donors causing ﬂuctuations in the H2S
evels and making the dosing more complicated than with the HTB
r ADT-OH-based donors. While the beneﬁcial effects of garlic in
iabetes models were conﬁrmed by multiple studies [29–31,66],
arlic had no effect on endothelial function and oxidative stress in
iabetic patients in a recent pilot trial and only little increase was
etected in the glutathione level [67], which further support the
ifﬁculties with dosing of garlic-based dietary supplements.
. Conclusion
Mitochondrial slow release H2S donors provide protection
gainst the prolonged low level oxidative stress induced by hyper-
lycemia in endothelial cells. They increase the electron transfer
ate at respiratory complex III and have beneﬁcial effect on cellu-
ar bioenergetics. These compounds offer the potential to be much
afer than inorganic sulﬁde salts (Na2S or NaSH) and target deliv-
ry to mitochondria: the concentration of AP39 and AP123 that
esults in these positive effects are >2 orders of magnitude lower
han their maximum tolerated concentration in vitro, whereas
he cytoprotective concentration of inorganic sulﬁde salts is very
lose to their toxic concentrations [17]. Furthermore, the slow H2S
elease in biological buffers combined with high lipophilicity and
itochondria-targeting allows fewer drug administrations making
hese compounds preferable to previously used H2S donors.
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